Helsinn Group Introduces New AKYNZEO® Formulation
Helsinn Group, a well-established pharmaceutical company based in Lugano, Switzerland, recently made headlines with the announcement of its new formulation for AKYNZEO®. This medication plays a vital role in supporting cancer patients by preventing nausea and vomiting that often accompany chemotherapy treatments. The submission of this new formulation to the European Medicines Agency (EMA) marks a significant step forward in Helsinn’s mission to improve patient care.
The Importance of AKYNZEO® in Oncology
AKYNZEO® is designed specifically for individuals undergoing highly emetogenic cisplatin-based chemotherapy, as well as moderately emetogenic treatments. This combination medication, featuring both 5-HT3 and NK1 receptor antagonist capabilities, is the first of its kind approved for adults facing the challenges of cancer treatment. The prevention of nausea and vomiting is crucial in ensuring that patients can complete their treatments and maintain their quality of life during difficult times.
Innovative Formulation Benefits
The new formulation of AKYNZEO®, upon receiving approval, is expected to provide even more effective relief for cancer patients. The advancements in its formulation aim to enhance the overall effectiveness of the drug and offer additional benefits compared to the existing versions. Helsinn’s commitment to innovation promises to bring new hope to patients needing reliable medicinal support during their treatment journey.
Timeline for Launch
Helsinn anticipates that the new AKYNZEO® formulation will be ready for launch by the first half of 2026, pending regulatory approval. This timeline reflects Helsinn’s dedication to bringing timely solutions to the market, ensuring that patients have access to effective treatments as soon as possible.
Company Commitment and Expertise
Roberta Cannella, Chief Technical Officer at Helsinn, stated, "This submission brings us closer to offering patients a new option for AKYNZEO®. It not only demonstrates our commitment to enhancing patients’ quality of life but also our dedication to innovation in supportive care.” This statement underscores Helsinn’s long-standing commitment to fighting cancer and supporting patients through innovative solutions
About Helsinn Group
Established in 1976, Helsinn is a fourth-generation family-owned company. It focuses on providing and commercializing products that significantly improve the quality of life for cancer patients and those suffering from chronic diseases. With direct operations in the U.S. and a strong global presence across 190 countries, Helsinn’s reputation is built on integrity, passion, and commitment to quality—all essential characteristics that guide its business strategies.
Future Directions
Helsinn’s continued progress in developing new drugs and formulations indicates a robust future strategy centered on innovation and patient-centered care. With its roots deeply embedded in patient support and quality enhancement, Helsinn Group continues to lead in the oncology field by pioneering efforts that prioritize patient needs.
Contact Information
For more inquiries and further information about Helsinn Group and their product offerings, interested parties can reach out to:
Helsinn Group Media Contact:
Sabrina Perucchi
Group Communication Manager
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Email: Info-hhc@helsinn.com
Frequently Asked Questions
What is the purpose of the new AKYNZEO® formulation?
The new AKYNZEO® formulation aims to enhance the prevention of nausea and vomiting in patients undergoing chemotherapy treatments.
When is the new formulation of AKYNZEO® expected to be launched?
The expected launch for the new formulation of AKYNZEO® is in the first half of 2026, pending approval from the EMA.
Who is Helsinn Group?
Helsinn Group is a global pharmaceutical company that focuses on supportive care, oncology, and dermato-oncology, aiming to improve the quality of life for patients.
What are the main benefits of AKYNZEO®?
AKYNZEO® is the first fixed-dose combination approved for preventing both acute and delayed nausea and vomiting related to specific cancer therapies, providing critical support for patients.
How can I get in contact with Helsinn Group for more information?
For inquiries, you can reach Helsinn Group's media contact, Sabrina Perucchi, at +41 (0) 91 985 21 21 or through their email.
